Synapse - Works

Results (2950)

Nivolumab and daratumumab combination regimens for the treatment of relapsed and refractory multiple myeloma: Results of a randomized phase I/II clinical trial

Journal Article

Abdallah, A. O.; Lesokhin, A.; Wrobel, T.; Jamroziak, K.; Dytfeld, D.; Touzeau, C.; Suvannasankha, A.; Leleu, X.; Silbermann, R.; Khan, A. M.; more...
Frontiers in Hematology (2023)

Fulltext@MSK | Save

Unrelated donor hematopoietic cell transplantation

Book Section

Petersdorf, E. W.; Hsu, K.
In Hoffman, R.; Benz, E. J. Jr; Silberstein, L. E.; Heslop, H. E.; Weitz, J. I.; Salama, M. E.; Abutalib, S. A. (Eds.) Hematology: Basic Principles and Practice. 8th ed (2023)

Fulltext@MSK | Save

A dysfunctional program imprinted by Prostaglandin E2 signaling shuts off NK cell communication pathways and disables immunosurveillance of metastasis

Meeting Abstract

Pedde, A.; Baumann, T.; Kim, H.; Donakonda, S.; Bayerl, F.; Meiser, P.; Hirschberger, A.; Klement, C.; Grassmann, S.; Öllinger, R.; more...
European Journal of Immunology (2023)

Fulltext@MSK | Save

Dose escalation of ISB 1342, a novel CD38xCD3 bispecific antibody, in patients with relapsed / refractory multiple myeloma (RRMM)

Meeting Abstract

Kapoor, P.; Stevens, D. A.; Leleu, X.; Merzoug, K. B.; Karlin, L.; Manier, S.; Chalopin, T.; Hulin, C.; Perrot, A.; Berdeja, J. G.; more...
Blood (2023)

Fulltext@MSK | Save

Long-term efficacy and safety of elranatamab monotherapy in the phase 2 magnetismm-3 trial in relapsed or refractory multiple myeloma (RRMM)

Meeting Abstract

Tomasson, M.; Iida, S.; Niesvizky, R.; Mohty, M.; Bahlis, N. J.; Martinez-Lopez, J.; Koehne, G.; Otero, P. R.; Prince, H. M.; Viqueira, A.; more...
Blood (2023)

Fulltext@MSK | Save

Clinical factors associated with cytokine release syndrome and dosing recommendations for restarting elranatamab following an interruption

Meeting Abstract

Niesvizky, R.; Arnulf, B.; Mohty, M.; Nooka, A. K.; Manier, S.; Tomasson, M.; Bahlis, N. J.; Irby, D.; Hibma, J.; Viqueira, A.; more...
Blood (2023)

Fulltext@MSK | Save

Manufacturing, characterization and anti-tumor activity of allogeneic CD19-CAR cytokine-induced killer (CIK) cells engineered with non-viral sleeping beauty transposon system and armored with IL-18

Meeting Abstract

Contreras-Ruiz, L.; Pace, B.; Kohnke, D. E.; Viruet, L.; Adams, M.; Krisko, J. F.; Leesnitzer, N.; Velie, M.; Tettamanti, S.; Pisani, I.; more...
Blood (2023)

Fulltext@MSK | Save

Efficacy and safety of elranatamab in Black patients with relapsed/refractory multiple myeloma (RRMM): A Subgroup analysis of the magnetismm studies

Meeting Abstract

Varshavsky-Yanovsky, A.; Jethava, Y.; Stevens, D. A.; Nooka, A. K.; Stiff, P. J.; Perez-Cruz, I.; Leip, E.; Lesokhin, A.
Blood (2023)

Fulltext@MSK | Save

Whole-genome sequencing reveals distinct mutational signatures in multiple myeloma patients with African ancestry compared with those of non-African ancestry

Meeting Abstract

Maclachlan, K. H.; Blaney, P.; Cirrincione, A.; Chu, T. R.; Poos, A. M.; Brown, E. E.; Manasanch, E. E.; Hoering, A.; Hou, L. M.; Gagler, D.; more...
Blood (2023)

Fulltext@MSK | Save

Potent and target specific cytotoxicity of PRAME TCR mimic CAR T cells in KMT2A-rearranged AML patient-derived xenograft model

Meeting Abstract

Kirkey, D. C.; Robinson, L.; Hylkema, T.; Loeb, A.; Ries, R. E.; McKay, C.; Root, C.; Pardo, L.; Loeb, K. R.; Le, Q.; more...
Blood (2023)

Fulltext@MSK | Save